Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises
2.6.2024 15:30:00 EEST | Business Wire | Press release
Denodo, a leader in data management, announced that it has integrated NVIDIA NIM inference microservices into the Denodo Platform, as part of its focus on bolstering its rapidly expanding artificial intelligence (AI) capabilities.
The Denodo Platform's logical data management capabilities, combined with NVIDIA NIM, enable enterprise customers to:
- Rapidly curate and transform data into AI-ready pipelines to feed large language models (LLMs)
- Improve model accuracy and combat hallucinations by accessing trusted enterprise data through retrieval augmented generation (RAG) pipelines.
- Simplify secure, real-time access to distributed enterprise knowledge for generative AI applications
- Maintain data privacy/security and enforce granular access controls for AI models that access organizational data
- Fast-track AI/ML deployments from data prep to model scoring with NVIDIA NeMo, leveraging an integrated data fabric for enterprise data input into this process
NVIDIA NIM is a collection of cloud-native microservices that simplify and accelerate the deployment of generative AI models across a variety of environments, including the cloud, on-premises data centers, and workstations. It connects the power of the latest foundational AI models, securely deployed on NVIDIA’s accelerated infrastructure, with enterprise customers everywhere.
The Denodo Platform’s integration of NVIDIA NIM helps customers seamlessly leverage advanced AI capabilities within their data management workflows. It also helps enable enterprises to deploy and scale generative AI applications with unprecedented speed and efficiency. Key use cases include improved analytics and robust AI-driven insights across such verticals as financial services, healthcare, retail, and manufacturing, accelerating time to insight from diverse data sources. As an NVIDIA Metropolis partner, Denodo is working to deploy vision AI and vision language model (VLM) NIM microservices to streamline industrial processes and increase worker safety.
Using the Denodo Platform with NVIDIA NeMo can significantly boost SQL query generation accuracy for LLMs. RAG capabilities enable more trustworthy responses by enabling models to retrieve relevant knowledge from the data fabric before generating output, and the Denodo Platform helps to simplify and accelerate data access, while reducing errors, when models query the platform.
By integrating NVIDIA NIM, Denodo helps ensure that customers will be able to maintain full control over their AI deployments, whether on premises or in the cloud. The integration is set to deliver significant business benefits, including accelerated time to value and enhanced security for AI applications.
“I am thrilled by this integration, and I think it's a sign of the direction in which Denodo's logical data management capabilities can take us,” said Narayan Sundar, Senior Director-Strategic Alliances at Denodo. “Denodo is at the forefront of supporting RAG-enabled GenAI applications with real-time, governed, trusted data from an organization’s vast data estates, and I look forward to seeing the innovations, as they start to emerge, from enterprise customers that leverage the Denodo Platform with NVIDIA NIM integration.”
Learn more about the Denodo Platform with NVIDIA NIM integration.
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading logical data management platform for delivering data in the language of business, at the speed of business, for all data-related initiatives across the organization. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across enterprises in 30+ industries all over the world have received payback in less than six months. For more information, visit denodo.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240602559183/en/
Contact information
Media
pr@denodo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
